Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Deep Learning-Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening.
De Almeida Braga C, Bauvais M, Sujobert P, Heiblig M, Jullien M, Le Calvez B, Richard C, Le Roc'h V, Rault E, Hérault O, Peterlin P, Garnier A, Chevallier P, Bouzy S, Le Bris Y, Néel A, Graveleau J, Kosmider O, Paul-Gilloteaux P, Normand N, Eveillard M. De Almeida Braga C, et al. Among authors: le bris y. Int J Lab Hematol. 2024 Sep 14. doi: 10.1111/ijlh.14368. Online ahead of print. Int J Lab Hematol. 2024. PMID: 39275905
Role of red cell mass evaluation in myeloproliferative neoplasms with splanchnic vein thrombosis and normal hemoglobin value: a study of the France Intergroupe des Syndromes myeloprolifératifs.
Galtier J, Drevon L, Le Bris Y, Giraudier S, Wemeau M, Legros L, Luque Paz D, Girodon F, Kiladjian JJ, Mesguich C, Parrens M, Mediavilla C, Roy L, Guy A, Mansier O, Ianotto JC, James C. Galtier J, et al. Among authors: le bris y. Haematologica. 2024 Jun 1;109(6):1989-1993. doi: 10.3324/haematol.2023.284488. Haematologica. 2024. PMID: 38328854 Free PMC article. No abstract available.
Susceptibility to mycobacterial infection in VEXAS syndrome.
Riescher S, Lecomte R, Danic G, Graveleau J, Le Bris Y, Hello M, Guillouzouic A, Guardiolle V, Garnier A, Grossi O, Gaborit B, Néel A. Riescher S, et al. Among authors: le bris y. Rheumatology (Oxford). 2024 Feb 5:keae087. doi: 10.1093/rheumatology/keae087. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38317027
Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
Jullien M, Guillaume T, Le Bourgeois A, Peterlin P, Garnier A, Eveillard M, Le Bris Y, Bouzy S, Tessoulin B, Gastinne T, Dubruille V, Touzeau C, Mahé B, Blin N, Lok A, Vantyghem S, Sortais C, Antier C, Moreau P, Scotet E, Béné MC, Chevallier P. Jullien M, et al. Among authors: le bris y. Am J Hematol. 2024 Mar;99(3):350-359. doi: 10.1002/ajh.27191. Epub 2024 Jan 2. Am J Hematol. 2024. PMID: 38165016 Clinical Trial.
A p53 score derived from TP53 CRISPR/Cas9 HMCLs predicts survival and reveals a major role of BAX in the response to BH3 mimetics.
Durand R, Descamps G, Bellanger C, Dousset C, Maïga S, Alberge JB, Derrien J, Cruard J, Minvielle S, Lilli NL, Godon C, Le Bris Y, Tessoulin B, Amiot M, Gomez-Bougie P, Touzeau C, Moreau P, Chiron D, Moreau-Aubry A, Pellat-Deceunynck C. Durand R, et al. Among authors: le bris y. Blood. 2024 Mar 28;143(13):1242-1258. doi: 10.1182/blood.2023021581. Blood. 2024. PMID: 38096363
Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia.
Tamburini J, Mouche S, Larrue C, Duployez N, Bidet A, Salotti A, Hirsch P, Rigolot L, Carras S, Templé M, Favale F, Flandrin-Gresta P, Le Bris Y, Alary AS, Mauvieux L, Tondeur S, Delabesse E, Delhommeau F, Sujobert P, Kosmider O. Tamburini J, et al. Among authors: le bris y. Blood Adv. 2023 Dec 26;7(24):7576-7580. doi: 10.1182/bloodadvances.2023011916. Blood Adv. 2023. PMID: 37987760 Free PMC article. No abstract available.
Tocilizumab in combination with a standard induction chemotherapy in acute myeloid leukaemia patients (TOCILAM study): a single-centre, single-arm, phase 1 trial.
Peterlin P, Garnier A, Le Bourgeois A, Guillaume T, Le Bris Y, Theisen O, Béné MC, Eveillard M, Rimbert M, Jullien M, Planche L, Gaschet J, Chevallier P. Peterlin P, et al. Among authors: le bris y. EClinicalMedicine. 2023 Sep 28;64:102254. doi: 10.1016/j.eclinm.2023.102254. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37786451 Free PMC article.
Targeted High-throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.
Darlington M, Sujobert P, Kosmider O, Luque Paz D, Kaltenbach S, Figeac M, Hayette S, Mezaour N, Coquerelle S, Alary AS, Bidet A, Le Bris Y, Delabesse E, Davi F, Preudhomme C, Durand-Zaleski I, Macintyre E. Darlington M, et al. Among authors: le bris y. Hemasphere. 2023 Aug 24;7(9):e943. doi: 10.1097/HS9.0000000000000943. eCollection 2023 Sep. Hemasphere. 2023. PMID: 37637995 Free PMC article.
CARD11 gain of function upregulates BCL2A1 expression and promotes resistance to targeted therapies combination in B-cell lymphoma.
Decombis S, Bellanger C, Le Bris Y, Madiot C, Jardine J, Santos JC, Boulet D, Dousset C, Menard A, Kervoelen C, Douillard E, Moreau P, Minvielle S, Moreau-Aubry A, Tessoulin B, Roue G, Bidère N, Le Gouill S, Pellat-Deceunynck C, Chiron D. Decombis S, et al. Among authors: le bris y. Blood. 2023 Nov 2;142(18):1543-1555. doi: 10.1182/blood.2023020211. Blood. 2023. PMID: 37562004 Free article.
55 results